New drug aims to calm brain inflammation in rare autoimmune disease
Disease control
Not yet recruiting
This early study tests a new medicine, ART5803, in 30 adults with Anti-NMDAR encephalitis (brain inflammation) or related psychiatric disease caused by the same antibodies. The main goals are to check if the drug is safe and tolerable, and to see early signs it might help control…
Phase: PHASE2 • Sponsor: Arialys Australia Pty Ltd • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC